Evidence mapPaperPMID 42259655Full record

ReviewDiabetes, obesity & metabolism2026

Cardiovascular-Kidney-Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling.

Volker Foos, Jieling Chen, Phil McEwan, Marc Evans, Pardeep S Jhund, Paul R Kalra, Hongtu Zhu, David C Wheeler, Geraint Roberts, Martin R Cowie and 1 more

Abstract readReview
In one paragraph

Review in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Volker FoosHealth Economics and Outcomes Research Ltd, Cardiff, UK.ORCID https://orcid.org/0009-0001-1686-9080
Jieling ChenAstraZeneca R&D Pharmaceuticals, Gaithersburg, Maryland, USA.
Phil McEwanHealth Economics and Outcomes Research Ltd, Cardiff, UK.ORCID https://orcid.org/0000-0001-7488-9058
Marc EvansDiabetes Resource Centre, University Hospital Llandough, Cardiff, UK.ORCID https://orcid.org/0000-0003-0671-0778
Pardeep S JhundSchool of Cardiovascular and Metabolic Health, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.ORCID https://orcid.org/0000-0003-4306-5317
Paul R KalraDepartment of Cardiology, Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust, and University of Portsmouth, Portsmouth, UK.
Hongtu ZhuGillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-6781-2690
David C WheelerUK Centre for Kidney and Bladder Health, University College London, London, UK.ORCID https://orcid.org/0000-0003-0745-3478
Geraint RobertsHealth Economics and Outcomes Research Ltd, Cardiff, UK.ORCID https://orcid.org/0000-0003-2006-4581
Martin R CowieLate-Stage Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.ORCID https://orcid.org/0000-0001-7457-2552
Andrew H BriggsDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.ORCID https://orcid.org/0000-0002-0777-1997

Funding

AstraZeneca
6 · The paper itself

Abstract

aimsCardiovascular-kidney-metabolic (CKM) syndrome has developed into a global public health crisis. Although integrated care is increasingly used to treat patients with CKM, current health economic models fail to capture the value of considering the CKM syndrome as a unified condition. We present a conceptual framework to guide development of a new health economic model that captures value holistically across interconnected CKM domains. MATERIALS AND

methodsFollowing best-practice guidelines, we undertook a review of published literature to identify and connect the key biological drivers of the CKM syndrome. These insights were synthesised into a biological framework, which was simplified into a streamlined influence diagram of sufficient complexity to guide model development. Both framework and diagram were iteratively reviewed and developed based on feedback from clinicians, health economists and modelling specialists.

resultsA biological framework and influence diagram were developed to illustrate how the CKM syndrome's biological drivers interconnect and link to key clinical outcomes. We detail the components of these diagrams, explaining the rationale behind connections. We discuss how the proposed framework could inform a model for future health economic evaluation.

conclusionThere is a clear unmet need for comprehensive modelling of the CKM syndrome to support evidence-based decision-making and guide management of this highly prevalent, far-reaching disease. As more evidence has become available, the mathematical development, in the near future, of a long-term, holistic and flexible health economic model has become feasible, despite some gaps. This work seeks to shape a shared understanding of the challenges and opportunities in this developing field.

Indexed as

Cardio-Renal SyndromeCardiovascular DiseasesMetabolic SyndromeModels, EconomicCost-Benefit AnalysisHumanscardiorenalcardiovascularhealth economic modelmetabolic syndromeobesity

Identifiers

PMID42259655
PMCPMC13448888

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.